Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Not Ruling Out Creative Deals For ‘Tail End’ Brands

Executive Summary

A better value proposition and more in-tune marketing ideas would drive a more creative risk-sharing or asset swap-like arrangement for the oncology specialist’s more mature brands, says Roche CEO Severin Schwan.


Related Content

Sanofi Off-Patent Brands In Deal Hunter Lupin’s Sights?
Emerging Markets Earnings Roundup: Roche (Part 7)
Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study
Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Roche’s Breast Cancer Strategy Paying Off, But Diversification Difficult
Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use

Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts